Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07375524Phase 2Not Yet Recruiting

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

Role: lead

NCT06979674Phase 1Recruiting

Study of ESG406 in Adults With Solid Tumors

Role: lead

NCT04892342Phase 1Completed

Study of ESG401 in Adults With Solid Tumors

Role: lead

NCT05263739Phase 1Withdrawn

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

Role: lead

NCT05822843Phase 1Completed

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Role: lead

NCT06853444Phase 1Recruiting

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

Role: lead

All 6 trials loaded